Ascendis Pharma's high share price may risk investor returns...
Ascendis Pharma's high share price may risk investor returns as future revenue forecasts are less promising. While most investors are hopeful for a business turnaround, analysts are less confident.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more